Skip to main content
Premium Trial:

Request an Annual Quote

Assurex's GeneSight Gets Approval for Use in VA Facilities

NEW YORK (GenomeWeb) – Assurex Health today said that the US Department of Veterans Affairs has approved the firm's GeneSight Psychotropic test for use in VA facilities nationwide.

GeneSight Psychotropic measures and analyzes genomic variants that can affect a patient's response to a broad panel of medications prescribed for mental health conditions including depression, post-traumatic stress disorder, anxiety, bipolar disorder, and schizophrenia. The firm cited a study published last year in Pharmacogenetics and Genomics, which showed that patients whose medication selection was guided by GeneSight Psychotropic experienced a 70 percent greater improvement in depressive symptoms.

The VA approval also allows clinicians with the Department of Defense, the Bureau of Indian Affairs, and the Federal Bureau of Prisons to have access to the GeneSight Psychotropic test.

Mason, Ohio-based Assurex also offers the GeneSight MTHFR to help clinicians determine whether a patient may need additional folic acid supplementation; GeneSight ADHD for predicting response to ADHD medications; and GeneSight Analgesic for predicting response to opioid medications.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.